Company / Cash & Equivalents
C4 Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$74.6M
FY2025
5-year range
$29.8M / $126.6M
FY2022-FY2025
Trend
+34.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $127M to $75M over the past 2 years.
Based on SEC 10-K filings.
$75M in FY2025 with a 3-year CAGR of +35.9%.
Declined from $127M to $75M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +35.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +35.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 34.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.6M | +34.4% |
| FY2024 | $55.5M | -56.2% |
| FY2023 | $126.6M | +325.5% |
| FY2022 | $29.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026